Lung deposition and pharmacokinetics of nebulized cyclosporine in lung transplant patients

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 27, Issue 3, 2014, Pages 178-184

  Corcoran, T E ^a   Niven, R ^b   Verret, W ^b   Dilly, S ^b   Johnson, B A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b APT Pharmaceuticals ^*  (United States)

Author keywords

Aerosol deposition; Inhaled cyclosporine; Lung transplant

Indexed keywords

CYCLOSPORIN A; PENTETATE TECHNETIUM TC 99M; PROPYLENE GLYCOL; AEROSOL; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; RADIOPHARMACEUTICAL AGENT;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BREATHING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; LUNG; LUNG TRANSPLANTATION; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); NEBULIZER; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCINTIGRAPHY; STOMACH; TIME TO MAXIMUM PLASMA CONCENTRATION; ADULT; AEROSOL; AGED; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG MONITORING; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; OHIO; PATHOPHYSIOLOGY; PENNSYLVANIA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCINTISCANNING; SURGERY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; AGED; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG; LUNG TRANSPLANTATION; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; OHIO; PENNSYLVANIA; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M PENTETATE; TREATMENT OUTCOME;

EID: 84901715647     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2013.1042     Document Type: Article

References (26)

1. Iacono AT, Keenan RJ, Duncan SR, Smaldone GC, Dauber JH, Paradis IL, Ohori NP, Grgurich WF, Burckart GJ, Zeevi A, Delgado E, O'Riordan TG, Zendarsky MM, Yousem SA, and Griffith BP: Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am J Respir Crit Care Med. 1996;153(.4 Pt 1):1451-1455. (Pubitemid 26112616)
2. McCurry KR, Iacono AT, Dauber JH, Grgurich WF, Pham SM, Hattler BG, Keenan RJ, and Griffith BP: Lung and heartlung transplantation at the University of Pittsburgh. Clin Transpl. 1997:209-218
3. Iacono A, Dauber J, Keenan R, Spichty K, Cai J, Grgurich W, Burckart G, Smaldone G, Pham S, Ohori NP, Yousem SA, Williams P, Griffith B, and Zeevi A: Interleukin 6 and interferon-gamma gene expression in lung transplant recipients with refractory acute cellular rejection: Implications for monitoring and inhibition by treatment with aerosolized cyclosporine. Transplantation. 1997;64:263-269. (Pubitemid 27332670)
4. Keenan RJ, Iacono A, Dauber JH, Zeevi A, Yousem SA, Ohori NP, Burckart GJ, Kawai A, Smaldone GC, and Griffith BP: Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J Thorac Cardiovasc Surg. 1997;113:335-340; discussion 340-331
5. Iacono AT, Corcoran TE, Griffith BP, Grgurich WF, Smith DA, Zeevi A, Smaldone GC, McCurry KR, Johnson BA, and Dauber JH: Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans. Eur Respir J. 2004; 23:384-390. (Pubitemid 38344373)
6. Corcoran TE: Inhaled delivery of aerosolized cyclosporine. Adv Drug Deliv Rev. 2006;58:1119-1127
7. Kroshus TJ, Kshettry VR, Savik K, John R, Hertz MI, and Bolman RM 3rd: Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg. 1997;114:195-202. (Pubitemid 27364208)
8. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, Kirk R, Rahmel AO, Stehlik J, and Hertz MI: The Registry of the International Society for Heart and Lung Transplantation: 29th Adult Lung and Heart-Lung Transplant Report - 2012. J Heart Lung Transplant. 2012;31: 1073-1086
9. Iacono AT, Johnson BA, Grgurich WF, Youssef JG, Corcoran TE, Seiler DA, Dauber JH, Smaldone GC, Zeevi A, Yousem SA, Fung JJ, Burckart GJ, McCurry KR, and Griffith BP: A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med. 2006;354:141-150. (Pubitemid 43076711)
10. Coates AL, Green M, Leung K, Louca E, Tservistas M, Chan J, Ribeiro N, and Charron M: The challenges of quantitative measurement of lung deposition using 99mTc-DTPA from delivery systems with very different delivery times. J Aerosol Med. 2007;20:320-330. (Pubitemid 47463185)
11. Pitcairn G, and Newman S: Tissue attenuation corrections in gamma scintigraphy. J Aerosol Med. 1997;10:197-198
12. Burckart GJ, Smaldone GC, Eldon MA, Venkataramanan R, Dauber J, Zeevi A, McCurry K, McKaveney TP, Corcoran TE, Griffith BP, and Iacono AT: Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. Pharm Res. 2003;20:252-256. (Pubitemid 36269732)
13. Corcoran TE, Smaldone GC, Dauber JH, Smith DA, McCurry KR, Burckart GJ, Zeevi A, Griffith BP, and Iacono AT: Preservation of post-transplant lung function with aerosol cyclosporin. Eur Respir J. 2004;23:378-383. (Pubitemid 38344372)
14. Verbeken EK, Cauberghs M, Lauweryns JM, and van De Woestijne KP: Anatomy of membranous bronchioles in normal, senile and emphysematous human lungs. J Appl Physiol. 1994;77:1875-1884. (Pubitemid 24322448)
15. Verbeken EK, Cauberghs M, Mertens I, Lauweryns JM, and van De Woestijne KP: Tissue and airway impedance of excised normal, senile, and emphysematous lungs. J Appl Physiol. 1992;72:2343-2353
16. Weibel ER: Morphometry of the Human Lung. Springer, Berlin; 1963
17. Heyder J, Gebhardt J, Rudolf G, Schiller CF, and Stahlhofen W: Deposition of particles in the human respiratory tract in the size range of 0.005-15 micron. J Aerosol Sci. 1986;17: 811-825. (Pubitemid 17492310)
18. Heyder J: Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc. 2004;1: 315-320
19. Bendstrup KE, Chambers CB, Jensen JI, and Newhouse MT: Lung deposition and clearance of inhaled 99mTc-heparin in healthy volunteers. Am J Respir Crit Care Med. 1999;160(.5 Pt 1):1653-1658
20. Laube BL: In vivo measurements of aerosol dose and distribution: Clinical relevance. J Aerosol Med. 1996;9 Suppl 1:S77-S91
21. Ilowite JS, Gorvoy JD, and Smaldone GC: Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis. 1987;136:1445-1449. (Pubitemid 18030280)
22. Neuringer IP, Sloan J, Budd S, Chalermskulrat W, Park RC, Stonebraker JR, O'Neal WK, Aris RM, and Randell SH: Calcineurin inhibitor effects on growth and phenotype of human airway epithelial cells in vitro. Am J Transplant. 2005;5:2660-2670
23. Wang T, Noonberg S, Steigerwalt R, Lynch M, Kovelesky RA, Rodriguez CA, Sprugel K, and Turner N: Preclinical safety evaluation of inhaled cyclosporine in propylene glycol. J Aerosol Med. 2007;20:417-428
24. Oliyai R, Safadi M, Meier PG, Hu MK, Rich DH, and Stella VJ: Kinetics of acid-catalyzed degradation of cyclosporin A and its analogs in aqueous solution. Int J Pept Protein Res. 1994;43:239-247. (Pubitemid 24097176)
25. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, and Wacher VJ: Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin Pharmacol Ther. 1995;58:492-497
26. Knoop C, Vervier I, Thiry P, De Backer M, Kovarik JM, Rousseau A, Marquet P, and Estenne M: Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: Comparison between cystic fibrosis and other conditions. Transplantation. 2003;76:683-688. (Pubitemid 37072003).